Amgen price target raised to $340 from $327 at Truist
Truist raised the firm's price target on Amgen to $340 from $327 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The firm is anticipating a rebound from a traditionally softer start to the year, with strength in Q2 prints for commercial franchises within its c